> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Foresee Pharma NDA Accepted for Prostate Cancer
- URL: https://www.fdaweb.com/foresee-pharma-nda-accepted-for-prostate-cancer/
- Published: 2020-10-09T12:00:00.000Z
- Updated: 2026-09-14T16:32:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147842

FDA has accepted for review a Foresee Pharmaceuticals 505(b)(2) NDA for Camcevi 42mg, a ready-to-use six-month depot formulation of leuprolide mesylate, indicated for treating advanced prostate carcinoma patients. The agency has set a user fee review action target date of 5/27/2021\. The submission is based on data from a Phase 3 clinical study in 137 prostate carcinoma patients that demonstrated treatment with Camcevi every six months was effective, safe and well tolerated, according to the company.